Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 149

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 149
---
 Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on
our clinical stage assets and there are no active research and development programs.

Revenue. Revenue for
the whole of the Company for the years ended December 31, 2023, 2022 and 2021 is set out below.

|                                                           | (£ in thousands) | Year ended December 31, | 2023 |     |     | 2022 |     |     | 2021 |
|:----------------------------------------------------------|:-----------------|:------------------------|-----:|:----|:----|-----:|:----|:----|-----:|
| Revenue (Europe, including United Kingdom)                |                  |                         |  381 |     |     |  699 |     |     |  578 |
| Revenue (Rest of World)                                   |                  |                         |   -- |     |     |   -- |     |     |   -- |
| Total Revenue from continuing and discontinued operations |                  |                         |  381 |     |     |  699 |     |     |  578 |

| 76 |

Recent Developments

The Committed Equity Financing

On January 17, 2025, we entered into the Purchase Agreement withthe Selling Shareholder, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, have the right, but not the obligation, to sell tothe Selling Shareholder, andthe Selling Shareholder is obligated to purchase, up to $35.0 million of newly issued Depositary Shares. As consideration for the Seller Shareholder’s execution and delivery of the Purchase Agreement, we have agreed to pay the Commitment Fee to the Selling Shareholder.

We do not have a right to commence any sales of Depositary Shares tothe Selling Shareholder under the Purchase Agreement until the Commencement Date (as defined in the Purchase Agreement). Over the 36-month period from and after the Commencement Date (unless the Purchase Agreement is terminated earlier in accordance with its terms),the Selling Shareholder has no right to require us to sell any Depositary Shares tothe Selling Shareholder, butthe
Selling Shareholder is obligated to make purchases as we direct, subject to certain conditions. There are no upper limits on the price per share thatthe Selling Shareholder must pay for Depositary Shares. Actual sales of Depositary Shares